Where can Zilucoplan be purchased through regular channels?

Zilucoplan (Zilucoplan), as a new type of S1P receptor modulator, has gradually attracted attention in the treatment of autoimmune diseases in recent years, especially showing significant therapeutic potential in moderate to severe active ulcerative colitis (UC). The drug reduces the inflammatory response by selectively regulating the S1P1 receptor and reducing the migration of lymphocytes from lymphoid tissues to inflammatory sites. Compared with traditional immunosuppressants and biological agents, itridimod has the advantages of oral administration, strong targeting, and rapid onset of action. It provides a new treatment option for some patients who have poor response to TNF-α inhibitors.

In addition to ulcerative colitis, itrimod is currently undergoing clinical research in other autoimmune diseases such as Crohn's disease, atopic dermatitis and multiple sclerosis, showing potential for broad indication expansion, and it is expected that the application scenarios will be further expanded in the future.

Regarding purchase channels, since Itramod has not yet been approved for marketing in mainland China, it cannot be obtained through hospitals or the medical insurance system. If domestic patients need medication, they usually need to obtain it through cross-border medical services or overseas pharmacies. Currently, in the United States and Europe, the original drug has been launched by Pfizer under the trade name Velsipity. It is a legal and compliant prescription drug that can only be purchased with a doctor's prescription.

What needs special emphasis is that you should avoid purchasing on your own through informal channels to prevent the purchase of counterfeit drugs or substandard products, and it is recommended to use them under the guidance of a doctor throughout the process. In addition, currently, itrimod is still a drug within the patent protection period, and no generic version has yet been launched, which means that its price is relatively high and it imposes a large financial burden on domestic patients.

Overall, itridimod is a new targeted drug with important clinical prospects and has received positive clinical recognition overseas, but there are still channel restrictions for domestic use.

Reference materials:https://www.drugs.com/zilucoplan.html